ArticleInternational orthopaedics2026
Minimum ten-year results of total hip arthroplasty using an alkali- and heat-treated titanium Zweymüller-type stem.
Article in International orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Zweymüller femoral stem is a well-established design for cementless total hip arthroplasty (THA). However, long-term data are scarce on modified versions produced by different manufacturers. This study aimed to evaluate the ten year clinical and radiographic outcomes of the Elance stem, a modified Zweymüller-type prosthesis.
methodsWe retrospectively reviewed 82 primary THAs performed between 2013 and 2015 using the Elance stem. This stem features an alkali- and heat-treated bioactive surface and lacks the traditional trochanteric shoulder. The target roughness of the stem surface was 1.0 to 2.5 µm. The primary endpoint was survivorship with revision for any reason; the secondary endpoint was the rate of the aseptic loosening of the Elance stem.
resultsThe 10-year survivorship rate with revision for any reason was 53% (95% CI: 40-63%). Forty-one hips (50%) underwent revision surgery, with 40 of these revisions (98%) due to aseptic stem loosening. Additionally, four stems demonstrated radiographic loosening but had not yet undergone revision, resulting in a total stem loosening rate of 54%.
conclusionsThe Elance femoral stem demonstrated unacceptably low year survivorship. Design modifications, specifically the omission of the trochanteric shoulder and a lower surface roughness compared to the original Zweymüller design, likely compromised initial stability and long-term osseointegration. These findings emphasize that bioactive surface treatments cannot compensate for suboptimal stem design and that caution is warranted when adopting modified orthopaedic implants without robust long-term evidence.
Indexed as
Identifiers
42043540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.